Anabolic Steroid • Oral • Schedule III

Anavar: The Mildest Oral AAS — Educational Reference

Last updated: March 2026

Oxandrolone (Anavar) is an FDA-approved oral anabolic-androgenic steroid with a uniquely favorable anabolic-to-androgenic ratio. This educational reference covers its pharmacology, documented clinical applications in muscle wasting and burn recovery, hepatotoxicity risks, and suppression profile for harm reduction.

322–630
Anabolic:Androgenic Ratio
(androgenic ~24% of testosterone)
20–80mg
Reported Clinical Dose (Men)
2.5–10mg/day in women
9–10 hrs
Half-Life
Once or twice daily dosing

How Oxandrolone Works

Oxandrolone is a synthetic DHT derivative with a unique modification: an oxygen atom replaces the carbon-2 in the A-ring, increasing anabolic potency while dramatically reducing androgenic activity. The C-17α methyl group enables oral bioavailability.

💪
High Anabolic Selectivity

Oxandrolone binds androgen receptors with high affinity in muscle tissue. The 2-oxa modification creates a uniquely anabolic-selective compound — anabolic:androgenic ratio of approximately 322–630:24 vs testosterone's 100:100 baseline. This selectivity is why it's one of the few AAS with legitimate FDA-approved clinical applications and a safer profile in women.

🔬
DHT Derivative — No Aromatization

As a dihydrotestosterone derivative, oxandrolone cannot be aromatized to estrogen. There is no estrogenic activity, no water retention, and no gynecomastia risk from estrogen conversion. This makes it one of the cleanest AAS for lean tissue preservation without estrogenic side effects — though androgenic effects like DHT-related hair loss remain possible.

⚠️
17α-Alkylation & Hepatotoxicity

Despite its mild reputation, oxandrolone is 17α-alkylated and genuinely hepatotoxic. Elevated ALT and AST are common, particularly at higher doses or extended cycles. The liver stress is dose and duration dependent. "Mild" refers to its androgenic and estrogenic profile — not liver safety. Cycle lengths should be limited to 6–8 weeks with liver support.

📉
HPTA Suppression

Oxandrolone suppresses the hypothalamic-pituitary-testicular axis, though less severely than most other oral AAS. Endogenous LH and FSH are reduced, leading to decreased natural testosterone production. Recovery tends to be faster than with stronger androgens, but PCT with SERMs is still standard practice after cycles longer than 4 weeks in men.

What Clinical Literature Shows

Data from published clinical trials on oxandrolone — including FDA-approved indications for muscle wasting, burn recovery, and Turner syndrome.

Lean Mass Preservation in HIV Wasting (20mg/day, 12 weeks)
RCT data showing LBM gains vs placebo in HIV-associated muscle wasting
+2–4 kg LBM
Burn Recovery — Wound Healing & Muscle Preservation
Pediatric and adult burn studies showing oxandrolone's FDA-approved benefit
~30% faster LBM recovery
ALT/AST Elevation (hepatotoxicity)
Liver enzyme increase at 40–80mg/day — less than Dianabol but real
1.5–5× ULN
HPTA Suppression at 20mg/day
Testosterone suppression from baseline — milder than most orals
~40–60%
Lipid Profile Impact (HDL reduction)
HDL cholesterol decrease — cardiovascular risk factor, oral route compounds this
~30–40% HDL reduction

Side Effects & Risks

Hepatotoxicity (Liver Damage Risk)
Real despite "mild" reputation — 17α-alkylation causes measurable liver stress
MODERATE — dose/duration dependent
Androgenic Side Effects (Men)
Acne, male pattern baldness acceleration — lower risk than most AAS (androgenic ratio ~24)
LOW-MODERATE
Virilization in Women
Clitoromegaly, voice deepening, body hair — lowest virilization risk among oral AAS
LOW at 2.5–10mg/day
Cardiovascular Risk (Lipid Panel)
HDL suppression and LDL increase — oral route bypasses liver and worsens lipids
SIGNIFICANT — monitor lipids
HPTA Recovery Time Post-Cycle
Time for natural testosterone to return to baseline — faster than heavier AAS
4–8 weeks with PCT

Key Takeaways

✅ What We Know
  • FDA-approved for muscle wasting, burn recovery, Turner syndrome, and HIV wasting
  • Anabolic:androgenic ratio of ~322–630:24 — exceptionally anabolic-selective
  • Does not aromatize — no estrogen-related side effects
  • 9–10 hour half-life allows once or twice daily dosing
  • Still hepatotoxic — 17α-alkylation causes liver enzyme elevation
  • Lowest virilization risk among oral AAS — most studied AAS in women
  • Milder HPTA suppression than Dianabol, Anadrol, or Winstrol
  • Cycle lengths limited to 6–8 weeks to minimize liver impact
⚠️ What We Don't Know
  • Long-term cardiovascular outcomes in recreational bodybuilding doses poorly documented
  • Optimal TUDCA/NAC dosing for oxandrolone-specific hepatoprotection not established by RCT
  • Individual variation in 17α-methylation metabolism creates unpredictable hepatotoxicity
  • Exact virilization threshold dose in women — irreversible effects possible
  • "Mild" label creates dangerous underestimation of real hepatic and lipid risks

🛒 Liver Support & Monitoring

Any oral AAS cycle requires liver support and regular bloodwork. Don't skip these harm reduction basics — "mild" doesn't mean liver-safe.

Related Resources

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚠️ Legal & Medical Disclaimer

This page is for educational and harm reduction purposes only. It is not medical advice. Oxandrolone (Anavar) is a Schedule III controlled substance in the United States under the Anabolic Steroid Control Act of 1990. Possession, distribution, or use without a valid prescription is illegal and carries serious legal penalties. Anabolic steroids carry significant health risks including liver damage, cardiovascular disease, and hormonal disruption. Always consult a qualified physician before making any decisions regarding hormone use. MeetPeptide does not endorse or encourage the use of controlled substances.